BAY-73-6691

• CAT Number: I004048
• CAS Number: 794568-92-6
• Molecular Formula: C15H12ClF3N4O
• Molecular Weight: 356.73
• Purity: ≥95%
• Target: PDE9 Inhibitor
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term or -20 °C for long term
• IUPAC Name: 1-(2-chlorophenyl)-6-[(2R)-3,3,3-trifluoro-2-methylpropyl]-5H-pyrazolo[3,4-d]pyrimidin-4-one
• InChI: InChI=1S/C15H12ClF3N4O/c1-8(15(17,18)19)6-12-21-13-9(14(24)22-12)7-20-23(13)11-5-3-2-4-10(11)16/h2-5,7-8H,6H2,1H3,(H,21,22,24)/t8-/m1/s1
• InChIKey: FFPXPXOAFQCNBS-MRVPVSSYSA-N
• SMILES: C[C@H](CC1=NC2=C(C=NN2C3=CC=CC=C3Cl)C(=O)N1)C(F)(F)F

BAY 73-6691 (Cat.No:I004048) is a drug developed by Bayer for the treatment of Alzheimer/’s disease. It was the first compound developed that acts as a phosphodiesterase inhibitor selective for the PDE9A subtype. The PDE9A enzyme is expressed primarily in the brain, with high concentrations in the cerebellum, neocortex, striatum, and hippocampus, and acts to limit the cGMP-mediated signal transduction which occurs following glutamate binding to NMDA receptors.

Reference

1:Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-β peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimer/’s disease. Li J, Liu CN, Wei N, Li XD, Liu YY, Yang R, Jia YJ.Brain Res. 2016 Jul 1;1642:327-35. doi: 10.1016/j.brainres.2016.04.011. Epub 2016 Apr 9. PMID: 27071547 2:Phosphodiesterase-9 (PDE9) inhibition with BAY 73-6691 increases corpus cavernosum relaxations mediated by nitric oxide-cyclic GMP pathway in mice. da Silva FH, Pereira MN, Franco-Penteado CF, De Nucci G, Antunes E, Claudino MA.Int J Impot Res. 2013 Mar-Apr;25(2):69-73. doi: 10.1038/ijir.2012.35. Epub 2012 Oct 4. PMID: 23034509 3:The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. van der Staay FJ, Rutten K, Bärfacker L, Devry J, Erb C, Heckroth H, Karthaus D, Tersteegen A, van Kampen M, Blokland A, Prickaerts J, Reymann KG, Schröder UH, Hendrix M.Neuropharmacology. 2008 Oct;55(5):908-18. doi: 10.1016/j.neuropharm.2008.07.005. Epub 2008 Jul 12. PMID: 18674549